University Hospitals Birmingham Foundation Trust has implanted a wireless microcomputer into its first patient.
The wireless in-heart microcomputer was recently implanted into a patient at the Queen Elizabeth Hospital Birmingham. The device, called V-LAP, is implanted into the heart’s left atrium, and provides accurate data about the heart and its performance, including blood pressure measurements.
The information is sent in real-time to hospital staff, with the patient contacted if pressure is too high to ensure treatment can be delivered quickly and prevent water developing in the lungs (pulmonary oedema).
By providing regular data, doctors will be able to work with patients to actively manage their health conditions and reduce the need for them to be admitted to hospital.
The operation was performed by Professor Francisco Leyva, Dr Howard Marshall and Dr Sayqa Arif, Consultant Cardiologists. Professor Leyva said “This new device has the potential to combat three of the biggest problems relating to heart failure disease; low patient quality of life, repeat admissions to hospital and the astronomical cost to the healthcare system of readmissions due to acute heart failure.”
“Today, physicians base the treatment of heart failure on external signs and symptoms such as shortness of breath and gaining weight – which appear at a late stage, so the patient doesn’t get the medication they need to stable their condition early enough.”
“44% of patients are re-hospitalised within a year from the first acute event, so this device shows real promise in reducing those readmissions, and the costs associated.”
The operation is low risk and takes less than an hour, with patients discharged from hospital the next day following routine overnight observations. If rolled-out across the NHS the technology could benefit thousands of people.
The V-LAP device does not have a battery, and is remotely charged, feeding back data to Prof Leyva and his team as it does so. V-LAP has been produced by Vectorious Technologies, and has already been successfully implanted into a number of patients in Germany and Italy.
Oren Goldshtien, Vectorious’ CEO said “We believe the V-LAP monitor is a game changer in helping the one million people living with heart failure in the UK take control and manage their disease.”
“Heart failure patients deserve the best treatment and quality of life possible. We are very excited about running our study now in the UK, and would encourage existing patients at UHB to ask if they could be enrolled in our ongoing study.”
